Johnson & Johnson Price to Free Cash Flow Ratio 2010-2025 | JNJ
Historical price to free cash flow ratio values for Johnson & Johnson (JNJ) since 2010.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Johnson & Johnson Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2025-04-17 |
157.47 |
|
18.65 |
| 2024-12-31 |
143.47 |
$8.45 |
16.99 |
| 2024-09-30 |
159.49 |
$8.69 |
18.34 |
| 2024-06-30 |
142.76 |
$8.48 |
16.83 |
| 2024-03-31 |
153.27 |
$7.59 |
20.19 |
| 2023-12-31 |
150.72 |
$7.27 |
20.74 |
| 2023-09-30 |
148.58 |
$6.28 |
23.66 |
| 2023-06-30 |
156.76 |
$5.63 |
27.87 |
| 2023-03-31 |
145.70 |
$6.23 |
23.38 |
| 2022-12-31 |
164.87 |
$6.65 |
24.77 |
| 2022-09-30 |
151.49 |
$6.80 |
22.28 |
| 2022-06-30 |
163.51 |
$7.60 |
21.50 |
| 2022-03-31 |
162.21 |
$7.52 |
21.58 |
| 2021-12-31 |
155.57 |
$7.65 |
20.32 |
| 2021-09-30 |
145.91 |
$8.72 |
16.73 |
| 2021-06-30 |
147.96 |
$8.77 |
16.87 |
| 2021-03-31 |
146.70 |
$8.14 |
18.02 |
| 2020-12-31 |
139.60 |
$7.67 |
18.19 |
| 2020-09-30 |
131.15 |
$6.91 |
18.98 |
| 2020-06-30 |
123.07 |
$6.65 |
18.51 |
| 2020-03-31 |
113.96 |
$8.50 |
13.40 |
| 2019-12-31 |
125.97 |
$8.64 |
14.59 |
| 2019-09-30 |
110.96 |
$9.35 |
11.87 |
| 2019-06-30 |
118.56 |
$8.74 |
13.56 |
| 2019-03-31 |
118.19 |
$8.04 |
14.70 |
| 2018-12-31 |
108.39 |
$7.97 |
13.61 |
| 2018-09-30 |
115.31 |
$7.48 |
15.42 |
| 2018-06-30 |
100.60 |
$7.70 |
13.06 |
| 2018-03-31 |
105.46 |
$7.36 |
14.32 |
| 2017-12-31 |
114.25 |
$7.14 |
16.00 |
| 2017-09-30 |
105.66 |
$7.11 |
14.86 |
| 2017-06-30 |
106.84 |
$6.62 |
16.13 |
| 2017-03-31 |
99.92 |
$6.33 |
15.78 |
| 2016-12-31 |
91.82 |
$6.03 |
15.24 |
| 2016-09-30 |
93.50 |
$5.86 |
15.94 |
| 2016-06-30 |
95.38 |
$6.19 |
15.40 |
| 2016-03-31 |
84.47 |
$6.66 |
12.69 |
| 2015-12-31 |
79.62 |
$6.96 |
11.44 |
| 2015-09-30 |
71.83 |
$6.13 |
11.72 |
| 2015-06-30 |
74.42 |
$6.80 |
10.94 |
| 2015-03-31 |
76.26 |
$6.56 |
11.63 |
| 2014-12-31 |
78.72 |
$6.85 |
11.49 |
| 2014-09-30 |
79.72 |
$6.76 |
11.80 |
| 2014-06-30 |
77.72 |
$5.83 |
13.34 |
| 2014-03-31 |
72.47 |
$5.49 |
13.20 |
| 2013-12-31 |
67.09 |
$4.96 |
13.52 |
| 2013-09-30 |
63.06 |
$4.94 |
12.78 |
| 2013-06-30 |
61.99 |
$4.71 |
13.15 |
| 2013-03-31 |
58.42 |
$4.64 |
12.59 |
| 2012-12-31 |
49.83 |
$4.97 |
10.03 |
| 2012-09-30 |
48.56 |
$5.02 |
9.68 |
| 2012-06-30 |
47.18 |
$5.05 |
9.34 |
| 2012-03-31 |
45.62 |
$4.83 |
9.45 |
| 2011-12-31 |
44.96 |
$4.59 |
9.79 |
| 2011-09-30 |
43.26 |
$4.62 |
9.36 |
| 2011-06-30 |
44.78 |
$4.71 |
9.51 |
| 2011-03-31 |
39.55 |
$4.72 |
8.38 |
| 2010-12-31 |
40.91 |
$5.21 |
7.85 |
| 2010-09-30 |
40.63 |
$5.76 |
7.05 |
| 2010-06-30 |
38.37 |
$5.69 |
6.74 |
| 2010-03-31 |
41.98 |
$5.50 |
7.63 |
| 2009-12-31 |
41.15 |
$5.15 |
7.99 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$394.223B |
$88.821B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
